The role of medications in managing postmenopausal osteoporosis.

Cosman Saag*

Department of Medicine, Columbia University, New York, NY, USA

Abstract

Postmenopausal osteoporosis is a significant health issue affecting millions of women worldwide. Medications play a crucial role in preventing bone loss and reducing fracture risk in postmenopausal women. This article provides a comprehensive review of the medications used in the management of postmenopausal osteoporosis, including bisphosphonates, selective estrogen receptor modulators, calcitonin, denosumab, and teriparatide. The efficacy, safety, and side effects of these medications are discussed, and recommendations are provided for selecting the most appropriate medication for individual patients.

Keywords: Postmenopausal osteoporosis, Bisphosphonates, Selective estrogen receptor modulators, Calcitonin, Denosumab, Teriparatide.

Introduction

Postmenopausal osteoporosis is a significant health problem affecting millions of women worldwide. It is a condition characterized by a decrease in bone density, leading to an increased risk of fractures, particularly in the hip, spine, and wrist. While lifestyle modifications, such as exercise and diet, can help improve bone health, medication therapy is often necessary to prevent and treat osteoporosis in postmenopausal women. This article will discuss the different types of medications used to manage postmenopausal osteoporosis, their mechanisms of action, and their benefits and side effects.

Bisphosphonates

Bisphosphonates are a class of drugs that are commonly used to treat osteoporosis in postmenopausal women. These drugs work by inhibiting bone resorption and reducing the activity of osteoclasts, the cells responsible for breaking down bone tissue. Bisphosphonates are available in both oral and intravenous formulations and have been shown to decrease the risk of vertebral, hip, and non-vertebral fractures. Examples of bisphosphonates include alendronate, risedronate, ibandronate, and zoledronic acid. Alendronate and risedronate are taken orally once a week, while ibandronate can be taken once a month orally or intravenously. Zoledronic acid is given intravenously once a year. While bisphosphonates are generally safe and well-tolerated, they can cause gastrointestinal side effects, such as nausea and abdominal pain. Rare but serious side effects include osteonecrosis of the jaw and atypical femur fractures. Patients taking bisphosphonates should also be monitored for hypocalcemia, as these drugs can reduce calcium levels in the blood [1].

Selective Estrogen Receptor Modulators (SERMs)

SERMs are a class of drugs that selectively bind to estrogen receptors and have both estrogenic and anti-estrogenic effects. Raloxifene is a SERM that is FDA-approved for the prevention and treatment of postmenopausal osteoporosis. It works by increasing bone mineral density and reducing the risk of vertebral fractures. Raloxifene is taken orally once a day and is generally well-tolerated. However, it can increase the risk of blood clots, including deep vein thrombosis and pulmonary embolism. It is also associated with hot flashes, leg cramps, and other mild side effects [2].

Parathyroid Hormone (PTH) analogs

PTH analogs, such as teriparatide and abaloparatide, are a newer class of drugs used to treat postmenopausal osteoporosis. They work by stimulating bone formation and increasing bone mineral density. These drugs are given by daily subcutaneous injection and have been shown to reduce the risk of vertebral and non-vertebral fractures. While PTH analogs are generally well-tolerated, they can cause nausea, dizziness, and leg cramps. Long-term safety data on these drugs is limited, and they are generally reserved for patients with severe osteoporosis who have failed other treatments.

Calcitonin

Calcitonin is a hormone produced by the thyroid gland that helps regulate bone turnover. Synthetic calcitonin is available as a nasal spray and is used to treat osteoporosis in postmenopausal women. It works by inhibiting bone resorption and reducing the risk of vertebral fractures. Calcitonin nasal spray is generally well-tolerated, but it can cause nasal irritation and nosebleeds. It is also associated with an increased risk of cancer and should be used with caution in patients with a history of cancer [3].

***Correspondence to:** Cosman Saag, Department of Medicine, Columbia University, New York, NY, USA, E-mail: cosman.saag78@he.edu.org

***Received:** 02-May-2023, Manuscript No. AAINM-23-98229; **Editor assigned:** 05-May-2023, PreQC No. AAINM-23-98229(PQ); **Reviewed:** 19-May-2023, QC No. AAINM-23-98229; **Revised:** 23-May-2023, Manuscript No. AAINM-23-98229(R); **Published:** 30-May-2023, DOI: 10.35841/aainm-7.3.150*

***Citation:** Saag C. The role of medications in managing postmenopausal osteoporosis. Insights Nutr Metab. 2023;7(3):150*

Denosumab

Denosumab is a monoclonal antibody that works by blocking the activity of osteoclasts, the cells responsible for breaking down bone tissue. It is administered via subcutaneous injection every six months. In clinical trials, denosumab has been shown to reduce the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis. It is generally well-tolerated, but some patients may experience side effects such as nausea, fatigue, and musculoskeletal pain. Rare but serious adverse effects include hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures [4].

Teriparatide

Teriparatide is a recombinant form of human parathyroid hormone (PTH) that stimulates bone formation. It is administered via subcutaneous injection once daily for up to two years. Clinical trials have shown that teriparatide reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. It is generally well-tolerated, but some patients may experience side effects such as headache, dizziness, and nausea. Rare but serious adverse effects include hypercalcemia and osteosarcoma.

Romosozumab

Romosozumab is a monoclonal antibody that works by blocking the activity of sclerostin, a protein that inhibits bone formation. It is administered via subcutaneous injection once a month for up to 12 months. In clinical trials, romosozumab has been shown to reduce the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. It is generally well-tolerated, but some patients may experience side effects such as injection site reactions, arthralgia, and headache. Rare but serious adverse effects include myocardial infarction and stroke [5].

Conclusion

Postmenopausal osteoporosis is a common condition that can have serious consequences, including fractures and disability. Pharmacological treatments are an important component of osteoporosis management and can significantly reduce the risk of fractures. Bisphosphonates are the most commonly prescribed medications for osteoporosis and have been shown to be safe and effective. Other medications such as calcitonin nasal spray, denosumab, teriparatide, and romosozumab may also be used in certain situations. The choice of medication depends on various factors such as patient characteristics, fracture risk, and comorbidities. Patients with osteoporosis should be closely monitored and receive regular bone density testing to evaluate treatment effectiveness.

References

1. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556-61.
2. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721-39.
3. Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309(22):1358-61.
4. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med. 2000;109(4):267-76.
5. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-91.

Citation: *Saag C. The role of medications in managing postmenopausal osteoporosis. Insights Nutr Metab. 2023;7(3):150*